This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Granzyme B Monoclonal Antibody (NGZB), PE-Cyanine5.5, eBioscience
catalog :
35-8898-82
quantity :
100 ug
price :
US 428.00
clonality :
monoclonal
host :
rat
conjugate :
PE-Cy5.5
clone name :
NGZB
reactivity :
mouse
application :
flow cytometry
citations: 42
Reference
Li J, Shi D, Li S, Shi X, Liu Y, Zhang Y, et al. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death Dis. 2024;15:175 pubmed publisher
Krug A, Tosolini M, Madji Hounoum B, Fourni xe9 J, Geiger R, Pecoraro M, et al. Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. J Exp Clin Cancer Res. 2024;43:43 pubmed publisher
Li K, Liu W, Yu H, Chen J, Tang W, Wang J, et al. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer. J Clin Invest. 2024;134: pubmed publisher
Wang Z, Li W, Jiang Y, Tran T, Cordova L, Chung J, et al. Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy. Nat Commun. 2023;14:7235 pubmed publisher
Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 2023;14:2859 pubmed publisher
Zhu Z, Tang R, Huff S, Kummetha I, Wang L, Li N, et al. Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. Cancer Res Commun. 2023;3:119-129 pubmed publisher
Wu Y, Zhou L, Zou Y, Zhang Y, Zhang M, Xu L, et al. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat Cancer. 2023;4:382-400 pubmed publisher
Li Q, Zhang L, You W, Xu J, Dai J, Hua D, et al. PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat Commun. 2022;13:7677 pubmed publisher
Wang W, Wu S, Cen Z, Zhang Y, Chen Y, Huang Y, et al. Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy. Cell Rep. 2022;41:111582 pubmed publisher
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022;132: pubmed publisher
Wong S, McCarroll J, Hsu K, Geczy C, Tedla N. Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment. Front Immunol. 2022;13:826391 pubmed publisher
Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, et al. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022;10: pubmed publisher
Ren J, Li N, Pei S, Lian Y, Li L, Peng Y, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated anti-tumor immunity. J Clin Invest. 2022;: pubmed publisher
Maity S, Chakraborty A, Mahata S, Roy S, Das A, Sen M. Wnt5A Signaling Blocks Progression of Experimental Visceral Leishmaniasis. Front Immunol. 2022;13:818266 pubmed publisher
Reyes R, Zhang C, Deng Y, Ji N, Mukherjee N, Padrón A, et al. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. Oncoimmunology. 2021;10:2006529 pubmed publisher
Wang Z, Ran L, Chen C, Shi R, Dong Y, Li Y, et al. Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma. Vaccines (Basel). 2021;9: pubmed publisher
Li J, Wang S, Wang N, Zheng Y, Yang B, Wang X, et al. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration. Cell Commun Signal. 2021;19:89 pubmed publisher
Dodagatta Marri E, Ma H, Liang B, Li J, Meyer D, Chen S, et al. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 2021;36:109309 pubmed publisher
Steele L, Mannion A, Shaw G, MacLennan K, Cook G, Rudd C, et al. Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection. iScience. 2021;24:102555 pubmed publisher
Yang N, Ji F, Cheng L, Lu J, Sun X, Lin X, et al. Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment. NPJ Precis Oncol. 2021;5:37 pubmed publisher
Luo Z, Xia K, Liu Y, Liu J, Rao S, Hu X, et al. Extracellular Vesicles from Akkermansia muciniphila Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages. Int J Nanomedicine. 2021;16:2949-2963 pubmed publisher
Daneshmandi S, Cassel T, Lin P, Higashi R, Wulf G, Boussiotis V, et al. Blockade of 6-phosphogluconate dehydrogenase generates CD8+ effector T cells with enhanced anti-tumor function. Cell Rep. 2021;34:108831 pubmed publisher
Liu J, Wang C, Cheng T, Rixiati Y, Ji C, Deng M, et al. Circadian Clock Disruption Suppresses PDL1+ Intraepithelial B Cells in Experimental Colitis and Colitis-Associated Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2021;12:251-276 pubmed publisher
Ebelt N, Zuniga E, Marzagalli M, Zamloot V, Blazar B, Salgia R, et al. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines. 2020;8: pubmed publisher
Utz B, Turpin R, Lampe J, Pouwels J, Klefstrom J. Assessment of the WAP-Myc mouse mammary tumor model for spontaneous metastasis. Sci Rep. 2020;10:18733 pubmed publisher
Parra M, Weitner M, Yang A, Akue A, Liu X, Schmidt T, et al. Memory CD73+IgM+ B cells protect against Plasmodium yoelii infection and express Granzyme B. PLoS ONE. 2020;15:e0238493 pubmed publisher
Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421 pubmed publisher
Wu J, Li S, Li T, Lv X, Zhang M, Zang G, et al. pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG. J Immunol Res. 2019;2019:1749803 pubmed publisher
Wang F, Meng M, Mo B, Yang Y, Ji Y, Huang P, et al. Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function. Nat Commun. 2018;9:4874 pubmed publisher
Wilgenburg B, Loh L, Chen Z, Pediongco T, Wang H, Shi M, et al. MAIT cells contribute to protection against lethal influenza infection in vivo. Nat Commun. 2018;9:4706 pubmed publisher
Cobbold S, Adams E, Howie D, Waldmann H. CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development. Front Immunol. 2018;9:1381 pubmed publisher
Kim D, Park H, Lim S, Koo J, Lee H, Choi J, et al. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. Nat Commun. 2018;9:503 pubmed publisher
Krzywinska E, Kantari Mimoun C, Kerdiles Y, Sobecki M, Isagawa T, Gotthardt D, et al. Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun. 2017;8:1597 pubmed publisher
Klein Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, et al. NFATc1 controls the cytotoxicity of CD8+ T cells. Nat Commun. 2017;8:511 pubmed publisher
Kim K, Bae S, Capece T, Nedelkovska H, de Rubio R, Smrcka A, et al. Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. Nat Commun. 2017;8:15365 pubmed publisher
Miao T, Symonds A, Singh R, Symonds J, Ogbe A, Omodho B, et al. Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation. J Exp Med. 2017;214:1787-1808 pubmed publisher
Allen E, Jabouille A, Rivera L, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9: pubmed publisher
Dai K, Huang L, Huang Y, Chen Z, Yang L, Jiang Y. 1810011o10 Rik Inhibits the Antitumor Effect of Intratumoral CD8+ T Cells through Suppression of Notch2 Pathway in a Murine Hepatocellular Carcinoma Model. Front Immunol. 2017;8:320 pubmed publisher
Sonner J, Deumelandt K, Ott M, Thomé C, Rauschenbach K, Schulz S, et al. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology. 2016;5:e1240858 pubmed publisher
Teo T, Her Z, Tan J, Lum F, Lee W, Chan Y, et al. Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology. J Virol. 2015;89:7955-69 pubmed publisher
Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241 pubmed publisher
Hou H, Liu W, Wu S, Lu Y, Peng J, Zhu Y, et al. Tim-3 negatively mediates natural killer cell function in LPS-induced endotoxic shock. PLoS ONE. 2014;9:e110585 pubmed publisher
product information
Product Type :
Antibody
Product Name :
Granzyme B Monoclonal Antibody (NGZB), PE-Cyanine5.5, eBioscience
Catalog # :
35-8898-82
Quantity :
100 ug
Price :
US 428.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Rat
Reactivity :
Mouse
Applications :
Flow Cytometry: 1.0 ug/test
Species :
Mouse
Clone :
NGZB
Isotype :
IgG2a, kappa
Storage :
4 C, store in dark, DO NOT FREEZE!
Description :
Granzyme B is a member of the granzyme serine protease family, and is found in the granules of cytotoxic T cells and NK cells. Granzyme B has been described as CGL1 (cathepsin G-like-1), a serine protease expressed only in cytotoxic T-lymphocytes after cell activation, and CTLA-1 (cytotoxic T lymphocyte-associated serine esterase 1) based on identification of mRNA in various cytotoxic T cells, but not observed in non-cytotoxic lymphoid cells. Granzyme B is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. The receptor involved in this process has been identified as mannose 6-phosphate receptor which functions as a death receptor for Granzyme B during cytotoxic T cell-induced apoptosis. Granzyme B enters target cells to cleave caspase-3 and initiate the caspase cascade leading to DNA fragmentation and apoptosis. Granzyme B can also act through a mitochondrial apoptosis pathway by cleaving the Bid protein. Granzymes are neutral serine proteases, which are stored in specialized lytic granules of cytotoxic T lymphocytes (CTLs) and in natural killer (NK) cells. A number of granzymes (A to G) have been isolated and cloned from mouse CTLs and NK cells, however in man, fewer have been cloned and identified.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 1.0 ug/test
Aliases :
AI553453; C11; Cathepsin G-like 1; CCP1; CCP-1/C11; CCPI; CGL1; CGL-1; CSPB; CSP-B; Ctla1; Ctla-1; CTSGL1; cytotoxic cell protease 1; cytotoxic serine protease B; Cytotoxic T lymphocyte associated serine esterase 1; cytotoxic T-lymphocyte proteinase 2; cytotoxic T-lymphocyte-associated serine esterase 1; fragmentin; fragmentin 2; fragmentin-2; GLP I; GLP III; GLP-1; granzyme 2; granzyme B; granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1); granzyme B(G,H); Granzyme-2; GranzymeB; granzyme-like protein 1; granzyme-like protein I; GRB; GZB; Gzmb; HLP; human lymphocyte protein; Human lymphocyte protein (Hlp); Lymphocyte protease; Natural killer cell protease 1; OTTHUMP00000028189; RNKP-1; SECT; T-cell serine protease 1-3E
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA